A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/12 (2006.01) A61K 39/145 (2006.01)
Patent
CA 2627971
The present invention relates to vaccine products for the treatment or prevention of viral infections. Further provided are methods of reducing contaminants associated with the preparation of cell culture vaccines. Residual functional cell culture DNA is degraded by treatment with a DNA alkylating agent, such as .beta.-propiolactone (BPL), thereby providing a vaccine comprising immunogenic proteins derived from a virus propagated on cell culture, substantially free of residual functional cell culture DNA.
La présente invention concerne des produits de vaccin conçus pour traiter ou prévenir des infections virales. Elle concerne également des procédés pour réduire les contaminants associés à la préparation de vaccins par culture cellulaire. L'ADN de culture cellulaire fonctionnel résiduel est dégradé par un traitement avec un agent d'alkylation d'ADN, tel que de la ß-propiolactone (BPL), fournissant alors un vaccin qui comprend des protéines immunogènes dérivées d'un virus propagé sur une culture cellulaire, sensiblement exempt d'ADN de culture cellulaire fonctionnel résiduel.
Gregersen Jens-Peter
Kost Holger
Borden Ladner Gervais Llp
Novartis Vaccines And Diagnostics Gmbh & Co Kg
LandOfFree
Cell-derived viral vaccines with low levels of residual cell... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cell-derived viral vaccines with low levels of residual cell..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cell-derived viral vaccines with low levels of residual cell... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1970211